Profile data is unavailable for this security.
About the company
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
- Revenue in USD (TTM)825.30m
- Net income in USD-400.50m
- Incorporated1992
- Employees2.70k
- LocationMyriad Genetics Inc322 North 2200 WestSALT LAKE CITY 84116United StatesUSA
- Phone+1 (801) 584-3600
- Fax+1 (801) 584-3640
- Websitehttps://myriad.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Evolent Health Inc | 2.05bn | -180.89m | 311.37m | 4.50k | -- | 0.3697 | -- | 0.1516 | -1.57 | -1.57 | 17.85 | 7.55 | 0.829 | -- | 5.17 | 456,456.00 | -5.17 | -5.93 | -6.41 | -8.00 | 18.42 | 21.07 | -6.24 | -7.16 | -- | 0.189 | 0.5572 | -- | 30.09 | 30.04 | 34.31 | -- | -6.87 | -- |
| Delcath Systems Inc | 79.60m | 1.20m | 328.77m | 96.00 | 1,070.12 | 2.86 | 235.85 | 4.13 | 0.0087 | 0.0087 | 2.10 | 3.25 | 1.02 | 1.26 | 7.70 | 829,197.90 | 1.54 | -94.54 | 1.90 | -143.97 | 86.29 | 81.31 | 1.50 | -339.85 | 13.71 | -- | 0.00 | -- | 1,701.70 | 88.10 | 44.66 | -- | 87.69 | -- |
| Rxsight Inc | 142.09m | -35.73m | 330.58m | 498.00 | -- | 1.20 | -- | 2.33 | -0.8782 | -0.8782 | 3.50 | 6.72 | 0.4591 | 1.40 | 5.74 | 285,313.30 | -11.54 | -19.50 | -12.45 | -21.50 | 74.98 | 57.17 | -25.15 | -52.00 | 11.44 | -- | 0.0004 | -- | 57.09 | 128.61 | 43.52 | -- | 5.89 | -- |
| Clearpoint Neuro Inc | 34.33m | -23.14m | 403.09m | 115.00 | -- | 24.27 | -- | 11.74 | -0.8264 | -0.8264 | 1.23 | 0.5584 | 0.6829 | 1.95 | 7.52 | 298,539.10 | -46.03 | -35.94 | -54.48 | -41.48 | 61.31 | 63.49 | -67.40 | -74.87 | 5.56 | -92.37 | 0.6479 | -- | 31.04 | 22.85 | 14.37 | -- | 11.41 | -- |
| Myriad Genetics Inc | 825.30m | -400.50m | 418.53m | 2.70k | -- | 1.12 | -- | 0.5071 | -4.34 | -4.34 | 8.97 | 4.00 | 0.9122 | 8.46 | 6.77 | 305,666.70 | -44.27 | -- | -53.15 | -- | 70.36 | -- | -48.53 | -- | 2.12 | -14.93 | 0.2427 | -- | 11.21 | -- | 51.65 | -- | -- | -- |
| Orthopediatrics Corp | 227.41m | -45.61m | 423.56m | 562.00 | -- | 1.21 | -- | 1.86 | -1.96 | -1.96 | 9.74 | 13.93 | 0.4628 | 0.5149 | 4.83 | 404,644.10 | -9.28 | -5.87 | -9.97 | -6.44 | 71.73 | 74.27 | -20.06 | -16.55 | 3.52 | -5.96 | 0.2214 | -- | 37.65 | 23.06 | -80.33 | -- | 4.29 | -- |
| Cerus Corp | 225.97m | -15.96m | 430.28m | 281.00 | -- | 7.00 | -- | 1.90 | -0.0848 | -0.0848 | 1.20 | 0.3201 | 1.12 | 1.99 | 8.35 | 804,163.70 | -7.91 | -20.38 | -12.30 | -31.96 | 60.50 | 61.15 | -7.09 | -25.37 | 1.29 | -1.04 | 0.5772 | -- | 7.78 | 16.51 | 44.20 | -- | -20.50 | -- |
| Standard Biotools Inc | 128.83m | -109.46m | 430.71m | 818.00 | -- | 1.08 | -- | 3.34 | -0.289 | -0.3383 | 0.3399 | 1.04 | 0.211 | 1.97 | 5.27 | 157,490.20 | -17.93 | -29.45 | -22.06 | -35.68 | 47.94 | 50.11 | -84.97 | -79.68 | 4.14 | -- | 0.0008 | -- | 64.03 | 8.27 | -147.67 | -- | 26.98 | -- |
| AngioDynamics, Inc. | 307.31m | -27.71m | 452.15m | 675.00 | -- | 2.59 | -- | 1.47 | -0.6731 | -0.6731 | 7.47 | 4.24 | 1.10 | 2.12 | 7.02 | 455,268.20 | -9.87 | -13.69 | -13.83 | -16.19 | 54.58 | 52.46 | -9.02 | -21.32 | 1.33 | -- | 0.0329 | -- | -3.76 | 2.06 | 81.56 | -- | -10.06 | -- |
| Neuropace Inc | 94.86m | -23.99m | 497.88m | 209.00 | -- | 27.05 | -- | 5.25 | -0.7535 | -0.7535 | 2.98 | 0.5564 | 0.9321 | 1.46 | 7.16 | 515,565.20 | -23.57 | -35.71 | -28.36 | -44.34 | 76.77 | 73.39 | -25.28 | -60.45 | 3.94 | -3.58 | 0.7603 | -- | 22.14 | 16.67 | 17.64 | -- | -8.15 | -- |
| Mesa Laboratories Inc | 247.54m | 3.73m | 500.49m | 730.00 | 140.00 | 2.68 | 17.41 | 2.02 | 0.6471 | 0.6471 | 44.81 | 33.79 | 0.5678 | 3.40 | 6.28 | 339,097.30 | 0.8564 | -8.81 | 1.13 | -9.71 | 62.40 | 61.98 | 1.51 | -25.15 | 1.45 | 1.62 | 0.4709 | -- | 11.47 | 15.41 | 99.22 | -- | 24.60 | 0.00 |
| Pacific Biosciences of California Inc | 160.01m | -546.38m | 516.26m | 575.00 | -- | 96.52 | -- | 3.23 | -1.84 | -1.84 | 0.5335 | 0.0177 | 0.1565 | 1.96 | 5.08 | -- | -53.45 | -22.47 | -59.23 | -24.40 | 33.97 | 33.11 | -341.47 | -214.45 | 2.44 | -19.72 | 0.9918 | -- | 3.89 | 15.19 | -76.34 | -- | -- | -- |
| Anteris Technologies Global Corp | 2.14m | -84.32m | 523.69m | 136.00 | -- | 55.68 | -- | 244.82 | -2.34 | -2.34 | 0.0594 | 0.1025 | 0.1065 | 1.53 | 11.88 | 15,728.75 | -420.16 | -- | -1,527.00 | -- | 67.94 | -- | -3,945.70 | -- | 0.8032 | -- | 0.046 | -- | -1.16 | -- | -65.77 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Myriad Genetics Inc's reporting currency: US Dollar USD
56.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 13.66m | 14.66% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.38m | 7.91% |
| Millennium Management LLCas of 31 Dec 2025 | 6.70m | 7.19% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 5.97m | 6.40% |
| Glenview Capital Management LLCas of 12 Jan 2026 | 4.94m | 5.30% |
| D. E. Shaw & Co. LPas of 30 Sep 2025 | 4.56m | 4.89% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 2.96m | 3.18% |
| Jacobs Levy Equity Management, Inc.as of 31 Dec 2025 | 2.27m | 2.44% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.23m | 2.39% |
| Camber Capital Management LPas of 30 Jun 2025 | 2.00m | 2.15% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
